412 compounds.
Brain, mood and sleep
37 listed10 up to 20 mg per day
Research only
Research only
Research only
No established dose. Isolated community reports around 300 mcg exist, but there is insufficient data for a community range and zero published studies of the defined 984 Da molecule.
No treatment dose. Amyloid beta is a laboratory reagent, not a therapeutic peptide. Historical Alzheimer's vaccine trials injected 50–225 mcg of aggregated Aβ42 with an immune adjuvant, but the program was stopped after cases of brain inflammation. Those trial doses are not a personal-use protocol.
30 mg per dose
5 up to 20 mg per day (start low, increase slowly)
No human dose. Preclinical studies used 100–1,000 mcg intranasally in rats and 0.3–10 mg/day in macaque dose-escalation work. These are not human dosing guidance.
0.1 up to 0.2 mg per dose (start low, increase slowly)
1 mg per day in the published human study
5 up to 15 mg per day
Research only
Research only
0.2 up to 0.4 mg per day
No established dose in people. It clears very quickly from blood, one reason the natural peptide itself has never been a plausible medicine, and any figure offered as a neurotensin dose would be invented.
10 up to 30 mg per day (start low, increase slowly)
No human dose established. P7C3 and P7C3-A20 remain preclinical, and P7C3 is a small molecule rather than a peptide.
No safe self-directed dose is established
1 up to 10 mg per day (start low, increase slowly)
125 to 1,000 mcg per dose (phase 1 single-dose part)
No human dose exists and no animal dose has been published. Any figure quoted for it would be invented.
0.25 up to 0.5 mg per day
0.2 up to 0.6 mg per day
No human dose exists. The animal work put it directly into the brain's fluid spaces by intracerebroventricular injection, a route with no home or clinic equivalent. Any dose quoted for it would be invented.
5 mg per dose, 10 mg a day (Japanese and Korean labels)
5,000 to 12,000 mg twice daily by weight (label)
2.4 up to 19.2 mcg per day by continuous pump (label)
Growth hormone
25 listed0.1 mg per dose
1 up to 2 mg per dose (start low, increase slowly)
2 to 3 mcg/kg per infusion (phase 2 trials)
Research only
0.1 up to 0.3 mg per dose (start low, increase slowly)
Research only
Research only
Research only
1 up to 3 IU per day (start low, increase slowly)
0.2 up to 0.3 mg per dose (start low, increase slowly)
0.24 mg/kg weekly
0.5 mg per kg, once
0.04 to 0.08 mg/kg twice daily to start, up to 0.12 mg/kg twice daily (label)
10 up to 25 mg per day
10 mcg twice daily (phase 3); 10 to 100 mcg in earlier trials
0.2 up to 0.5 mg per dose (start low, increase slowly)
0.16 to 0.24 mg/kg weekly
3.5 mcg/kg/hour
0.66 mg/kg weekly
1.28 up to 2 mg per day, depending on which product you have
0.096 to 0.8 mg once a day by body weight, from 3 kg up (label)
Healing and recovery
69 listedSet by the label
No established human dose
2.5 or 5 mg once weekly, by body weight (phase 3 trial)
2 million KIU loading dose, 2 million into the pump, then 500,000 KIU per hour (full-dose regimen)
1 up to 4 mg per day (start low, increase slowly)
Research only
0.75 mg/kg bolus, then 1.75 mg/kg/h during the procedure (label)
0.25 up to 0.5 mg per dose (start low, increase slowly)
Set by the label
400 to 1,600 mcg once weekly (phase 3 range; 600 mcg for the first 4 weeks)
10 up to 50 mL per day (start low, increase slowly)
Given in the hospital as a course of daily infusions
1.0 mg/kg every 6 hours, up to 13 doses over 72 hours (phase 2 trials)
75 mg once daily to 150 mg twice daily for 28 days (phase 1b trial)
0.5 mcg/kg after each dialysis session (label)
3 or 6 mg once daily (phase 2 trial)
180 mcg/kg bolus, then 2 mcg/kg/min (label)
5 mg to start, then 2.5 to 15 mg three times a week (label)
10 mg twice weekly (phase 3 trial)
0.2 up to 0.5 mg per day (start low, increase slowly)
One drop of 4 µM solution in both eyes three times a day (phase 2 trial)
72, 145 or 290 mcg once daily (label)
2.6 mg/kg once, up to 270 mg (trials)
200 or 400 mg twice weekly (phase 2 trial)
Set by the device; the peptide mass per unit is not published
The label states no strength for the peptide, so there is no dose to calculate here. A dentist applies the product as supplied, and the retail toothpastes are used like any toothpaste.
18 mcg once daily to start, adjusted within 6 to 30 mcg (label)
0.25 up to 0.5 mg per day (start low, increase slowly)
Supplied at 0.25 mg per mL, dosed by body weight
300 mg per day (100 mg three times a day)
Subcutaneous: 2 mg/kg per week
Dose not disclosed; taken once daily for 8 weeks in the trial
1 microgram per mL, one drop in each eye, in the published phase 2
3 mg once daily (label)
10 mg in hyaluronate gel, placed around the repaired tendon (phase 2 trial)
Enough gel to cover the bleeding area, from 1, 3 or 5 mL syringes of 2.5% gel (FDA 510(k) summary)
0.75 to 1.5 mg/kg daily for 5 days, or weekly (trial doses)
5 up to 10 mg per day
1 mcg/kg weekly to start, adjusted by platelet count up to 10 mcg/kg (label)
19 mg once a week to start, adjusted in steps from 9.5 to 108 mg (label)
0.2 mcg/kg once, or 0.4 mcg/kg for gastrinoma testing (label)
30 mcg/kg per day by continuous infusion for 48 hours (phase 3 trials)
0.02 mcg/kg over 30 to 60 seconds, with a second dose of 0.04 mcg/kg if needed (label)
0.3 mcg/kg, 3 doses a day on days 1, 3 and 6 (trial regimen)
Dosed by body weight in micrograms per kilogram. The calculator has no body-weight input, so it cannot produce a draw.
2 up to 2.5 mg per injection (start low, increase slowly)
0.05 mg per kg of body weight per day
1 to 100 mcg placed locally (trials)
Research only
0.05 mg per dose
Immune support
40 listed8.5 mg daily (US label)
Research only
One drop in each eye (eye drops, label)
4 to 6 mg/kg once daily (adults, label)
No human dose exists, because no person has ever received darobactin. There is no label, no route, no frequency, no supplied strength and nothing marketed. The only dose figures in existence are animal ones, all given by injection: in mice, 50 mg/kg into the abdomen as a single dose, or 25 mg/kg into the abdomen every 6 hours for three doses, or 25 mg/kg at 2, 8 and 14 hours in the thigh infection model; in zebrafish embryos, 10 mg/kg into the caudal vein. The engineered successor D22 has been given to mice at 2.5 to 75 mg/kg by vein, under the skin or into the abdomen, and at 20 mg/kg by mouth, where only 0.62% was absorbed. None of these are human doses and none can be scaled into one, so the calculator has nothing to draw.
No human dose exists and none has been proposed by anyone. The single animal experiment is a mouse systemic E. coli infection model in which treated mice survived; the dose, route and schedule sit in the paywalled full text of the 2022 paper and could not be read for this page. Any figure presented as a human dose would be invented.
90 mg twice daily (label)
100 to 300 mg per injection
Oral: 250 up to 1000 mg per day
No dose has been disclosed. Trade reporting suggests the multiple-dose stage of the first trial may compare daily with weekly dosing, and that is a report about a trial design rather than a dose. Any figure offered as an HCXT-2001 dose would be invented.
30 mg per attack (label)
200 mg once daily (label)
50 mcg per dose
0.1 up to 0.5 mg per dose (start low, increase slowly)
2 mg/m2 per infusion (EU label)
1,000 mcg with 250 mcg GM-CSF (PRESENT phase 3)
1% gel at catheter sites, 1.6% gel on rosacea (phase 3 trials)
200 mcg every 4 weeks (every trial to date)
1,080 mg twice weekly under the skin; 15 mg into the eye every 25 to 60 days
10 mg/kg IV every 8 hours (phase 2 trials)
0.8% cream twice daily (last trials)
0.5 mg/kg once, as a 10-minute infusion (phase 3 trial)
500 mcg of conjugate with 150 mcg GM-CSF (ACT IV phase 3)
500 mg a day in trials
No human dose exists and none has ever been proposed in a trial. Published figures are minimum inhibitory concentrations in culture and doses in mouse infection models, neither of which converts into a human dose. Any figure offered as a teixobactin dose would be invented.
0.56 to 1.12 mg per dose (phase 2a trial)
5 up to 10 mg per day (start low, increase slowly)
Varies (course-based)
50 mg per dose
1.6 mg per dose
1 mg per dose
Set by the product label, the infection and kidney function
23.7 mg (three 7.9 mg capsules) per dose (label)
A single intra-articular irrigation during the operation; the registry states no concentration
16.6, 23 or 32.4 mg daily, by body weight (label)
Longevity and energy
36 listedResearch only
Research only
25 mg per day in the phase 1b stage
3.2 mg/kg as a 1-minute push into a vein, the dose chosen for phase 2
2,000 mg infused twice weekly with radiotherapy and temozolomide (phase 3 trial)
5 up to 10 mg per day (start low, increase slowly)
Set by an FDA label, in international units
Research only
No human administration study has established a dose. Human evidence is limited to measuring circulating GDF-11; experimental administration remains animal work.
No human dose exists. The mouse work most often cited used recombinant Klotho at 0.01 mg per kg per day into the abdomen for ten weeks. Scaled naively to a person that is well under a milligram a day, and at research-grade prices that is thousands of dollars a day, which is a useful sanity check on what a cheap vial can plausibly contain.
500 mg once weekly (recommended phase 2 dose)
1 up to 5 mg per day (start low, increase slowly)
Research only
50 up to 100 mg per dose (start low, increase slowly)
250 up to 1,000 mg per day
8 mg/m2 every 2 weeks in the phase 2 trial
No human dose exists. Every chronic animal result came from a surgically implanted osmotic pump infusing 1.5 to 3 mg per kg per day under the skin for weeks to months; that is an infusion rate, not a bolus, and there is no published basis for scaling it to a person. The lab reports no oral bioavailability. No vendor or forum protocol was found, and that absence is the most useful thing to know about dosing this compound.
Research only
No human dose established. SHLP6 has not been administered in a published human trial; current literature is mechanistic and preclinical.
2 to 5 mg per day (community-reported)
0.5 to 12 mg/kg weekly in dose-finding (trial)
500 up to 2,000 mg per day
Prescription products are dosed by a clinician
5 to 6 mg/m2 of body surface, weekly or two weeks in three (trial doses)
36 to 480 mg/m2 in dose-finding (trial)
Muscle building
14 listed0.02 up to 3 mg/kg per dose
200 to 240 mg into one named muscle, in the trial
10 up to 30 mg/kg per month (trial doses)
No established dose
Research only
0.05 up to 0.15 mg per dose (start low, increase slowly)
0.02 up to 0.05 mg per day (start low, increase slowly)
0.1 up to 0.2 mg per dose (start low, increase slowly)
12.5 to 50 mg daily (phase 2 doses)
0.2 up to 0.4 mg per dose (start low, increase slowly)
Sexual and hormonal
47 listed20 ng/kg/min to start, adjusted every 5 minutes (label)
No established dose. Human studies used infusions: into the brachial artery, into a coronary artery as a bolus during angiography, and systemically at rates in the tens to hundreds of nanomoles per minute. Those are research infusion protocols under direct monitoring of blood pressure, not doses. Any figure offered as an apelin dose would be invented.
6.75 mg bolus, then 300 and later 100 mcg/min for up to 48 hours (EU label)
0.25 up to 1 mg per dose, twice a week
100 mcg once, after the baby is delivered (label)
0.1 micrograms per kilogram per minute on the Japanese label; the trial tested 0.02
No established dose, but the rates used in people are on record and they are tiny. The two Capricor trials ran it as a continuous infusion under the skin through a wearable Insulet pump: four 48-hour periods at 0.5, 1.0, 2.0 and 3.0 nanograms per kilogram per minute across up to eight days. The earlier 22-person study used higher rates over four hours, 10, 17.5 and 25 nanograms per kilogram per minute. These are infusion rates for a monitored setting with a pump, not doses anyone can draw up in a syringe, and any figure offered as a self-administered cenderitide dose would be invented.
Set by the label
50 mg per day for a 5-day course
0.25 mg (250 mcg) once, for the test (label)
Set by the label
Set by the label and the formulation
Nasal: 10 up to 40 mcg per day
No dose exists. Nothing has ever been given to a person. Published figures are receptor binding and signaling measurements in cells and tissue, and they do not convert into a dose. Any figure offered as an elabela dose would be invented.
No human dose has been disclosed. A 2022 NIH grant aimed to find a minimum effective dose in animals, with no result made public. The patent family's dose ranges are generic and not tied to ENDO-205. The phase 1 route is unconfirmed: a student newspaper reported an injection with a possible pill form, and a grant abstract describes vaginal absorption studies. Any dose quoted for it would be invented.
250 mcg once a day during ovarian stimulation (label)
0.1 up to 0.2 mg per dose (start low, increase slowly)
Set by the label
250 up to 500 IU per dose (alongside testosterone therapy)
One 50 mg implant every 12 months, releasing about 65 mcg a day (label)
75 up to 150 IU per dose (start low, increase slowly)
0.1 up to 0.2 mg per dose
60 to 120 mg every 4 weeks (label)
Set by the label and the depot formulation
7.4 GBq every 8 weeks, 4 doses (label)
400 mcg a day for endometriosis; 1600 mcg a day for early puberty (label)
2 mcg/kg bolus, then 0.01 mcg/kg/min infusion (label)
50 to 500 mcg three times daily, or a 10 to 40 mg monthly depot (label)
18 up to 40 IU per dose
0.3 to 0.9 mg twice daily, or 10 to 60 mg monthly LAR (label)
Research only
1.75 mg per dose
10.2 MBq every 8 weeks, 4 doses (phase 3)
0.85 to 1.7 mg every 6 hours (label)
Research only
Set by the label
Set by an FDA label
15 nanograms per kilogram per minute for 48 hours
No established dose. The heart failure work used a four-hour intravenous infusion given on top of standard care in the hospital, and an earlier chronic heart failure study used one-hour infusions at two fixed amounts. Those are monitored hospital infusion protocols, not doses that transfer anywhere else, and any figure offered as a urocortin-2 dose would be invented.
0.01 to 0.07 units/min in septic shock, 0.03 to 0.1 units/min after heart surgery (label)
Skin and cosmetic
46 listedUse level not public; 2% in the patent's concentrate solution, about 0.1% in its example cream and 3% in a cream the supplier tested (patent and 2021 review)
Set by the finished product
2% Diffuporine solution in a cream or serum (supplier)
Set by the finished product
Serum or cream, per product
BASF use level not public; 0.0015% in the supplier's volunteer test (2021 review)
2% Uplevity solution in a cream or serum (supplier), about 10 ppm peptide if the solution is 0.05% peptide
Serum or scalp treatment, 0.1 to 5%
Serum, per product
Set by the product; the laboratory work used 0.74 to 7.4 micrograms per mL
On the scalp: per product. Injected: no established amount
Serum, per product
Serum, 2 to 6 ppm typical in a finished product
1 to 2 mg per day injected (community practice). On the skin: per product
0.5 up to 2 mg per day injected (community practice). On the skin: per product
Set by the finished product
Supplier recommends 0.5 to 1.5 percent of the finished product
Serum, per product
Topical serum, per product
Per finished product instructions
0.5 up to 1 mg per day (loading phase)
0.25 up to 1 mg per dose (start low, increase slowly)
No dose can be established because Melanotan III is not a publicly characterized compound — no confirmed molecule, sequence, or clinical program matches the name.
Set by the finished product
Serum, per product
Serum, per product
Set by the finished product
A few ppm in the finished product (up to 0.002%)
Serum or cream, typically 200 mg of active per formulation batch
Serum or cream, per product
Serum or cream, typically 200 mg of active per formulation batch
Serum or cream, per product
Serum, per product
Serum, per product
Serum or cream, typically 4% of a supplied 200 mg batch
About 0.01% peptide in a cream or serum, as 5% Decorinyl (supplier)
No concentration has been published for any product containing it, and cosmetic ingredient levels are rarely disclosed. The dose is whatever the finished shampoo, treatment or oil contains.
Serum, per product
Weight loss and metabolic
80 listed2.5 up to 5 mg per day injected (the capsule dose is far higher, see below)
Oral: 50 up to 150 mg per day
No human dose has been disclosed for the phase 1. Monkeys received 10 to 30 mg/kg by mouth once daily, or 15 mg/kg twice daily, doses that do not translate to people. Any dose offered for it would be invented.
No approved dose. Phase 1 tested 4, 6 and 14 mg once weekly, 14 mg every other week and 8 mg monthly, over 12 to 13 weeks. Those are dose-finding amounts in 60 mostly male volunteers with an average body mass index just under 30, not a schedule anyone has been prescribed. The phase 2 doses have not been published.
0.03 mg/kg per day
No human dose. Registered human studies measure circulating adropin rather than administer it. Animal experiments have used species-specific doses that do not convert to human guidance.
42 mg/kg per dose
Was set by the label
0.3 up to 60 mg per week
Oral: 1 up to 100 mg per day
50 mcg into a vein (1998 kinetics study)
No human dose has been disclosed. The registry lists four ascending single doses and four ascending repeat doses without naming any of them, and the comparator cohort receives tirzepatide at its approved weekly dosing. Any figure offered as an ASC35 dose would be invented.
No human doses have been disclosed for any of the three phase 1 trials. The injection is designed for once monthly to once quarterly at 1 mL or less through a fine needle; the tablet for once daily. Monkeys received 10 or 25 mg tablets daily for a week, and rats 5 or 10 nmol/kg by injection every two days; neither translates to a human dose. Any dose offered for it would be invented.
No human dose exists and none has been proposed. The mouse studies used 1, 10 and 30 nanomoles per kilogram injected once daily for 11 days, a laboratory comparison and not a human dose. The tablet is intended to be weekly and the injection monthly, but neither schedule has been tested in a person. Any figure quoted as an ASC37 dose would be invented.
25 or 50 mg weekly (phase 2 doses)
90 mg once daily (phase 3 dose)
Once weekly in trials; milligram dose levels have not been publicly disclosed
Set by the Chinese label
0.4 up to 2.4 mg weekly, or 3.2 to 4.8 mg monthly (trial doses)
No dose has been disclosed. The phase 2 trial has six dose groups and the registry does not name any of them, and the phase 1 doses were never published either. Any figure offered as a BI 3034701 dose would be invented.
24 or 48 mg every two weeks, after a step-up from 3 mg (phase 3 trials)
0.3 up to 4.5 mg per dose (start low, increase slowly)
0.6 mg once, with one repeat after 15 minutes if needed (label)
0.75 up to 4.5 mg per week (start low, increase slowly)
2 up to 10 mg per week (trial doses, stepped up monthly)
1 up to 9 mg per week (trial doses)
20 mg once daily (label)
2 mg per week (the weekly form)
0.1 up to 0.3 mg per dose (start low, increase slowly)
1 mg injected or 3 mg into one nostril, once, with a second dose after 15 minutes if needed (label)
2.5 up to 10 mg per day
No doses have been disclosed in the registry or company releases. The company intends a once-weekly tablet. Any dose offered for it would be invented.
0.25 up to 0.5 mg per day (start low, increase slowly)
100 units a week to start
70 units a week to start
1 up to 12 mg per week (trial doses)
Varies widely by route and purpose
25 or 40 pmol/kg/min as a continuous infusion (two human studies)
No standard dose. The formula changes between pharmacies
0.6 up to 3 mg per day (start low, increase slowly)
Set by the label
140 up to 420 mg per month (trial doses)
2 up to 9 mg per dose (start low, increase slowly)
30 mg weekly for 4 weeks, then 120 to 180 mg monthly (trial regimens)
No human dose exists. The mouse work used twice-daily injections into the abdomen over 10 days, a single high dose in one arm, and implanted pumps delivering it continuously under the skin for two weeks in the longer studies; the paper's own pharmacokinetics put the half-life at 10.4 minutes, and that is why the injected schedules were so frequent. Nothing in that translates to a human dose, and any figure offered for one would be invented.
2.5 to 10 mg daily over 40 kg; 0.06 to 0.13 mg/kg at 40 kg or under (label)
Up to 150 mg once daily in the phase 2 trial
0.8 up to 17.2 mg per day (six steps, 30 days apart)
400 nmol (about 1.8 mg) under the skin before meals, three times daily (research studies)
Research only
1.2 up to 2.4 mg per week (trial doses)
No established dose. Research infusions were given by vein at rates set per kilogram per minute under monitoring, and at effective rates nausea was common enough to end one study arm for most participants. Those are infusion rates for a research setting, not doses, and any figure offered as a peptide YY dose would be invented.
1.0 up to 9.0 mg per week (trial maintenance doses, not an approved dose)
0.15 up to 1.2 mg weekly (phase 1 doses)
0.015 up to 0.12 mg per dose (start low, increase slowly)
1.0 mg once weekly, added to semaglutide 2.4 mg (phase 2 trial)
1 up to 12 mg per dose (start low, increase slowly)
2 up to 10 mg per week (trial doses)
0.25 up to 2.4 mg per week (start low, increase slowly)
2 up to 3 mg per day (start low, increase slowly)
No human dose. Animal research exposure was 25–35 mcg/kg/day in rodent metabolic experiments; human papers measure endogenous spexin rather than administer it.
2.4 up to 6 mg per week (start low, increase slowly)
2.5 up to 15 mg per week (start low, increase slowly)
2 to 6 mg per week (phase 2 trial)
2.5 up to 15 mg per week (start low, increase slowly)
20 mg weekly for 2 weeks, then 40 mg weekly (phase 2 trial)
80 up to 160 mg per month (trial doses)
Blends
18 listed0.25 up to 0.5 mg BPC-157 per day (the TB-500 follows your ratio)
0.25 up to 0.5 mg BPC-157 per day (the rest follows your ratio)
2.4 mg cagrilintide plus 2.4 mg semaglutide per week
0.1 mg CJC-1295 (no DAC) per dose (the rest follows your ratio)
0.1 mg CJC-1295 (no DAC) per dose (the rest follows your ratio)
0.1 mg CJC-1295 (no DAC) per dose (the rest follows your ratio)
0.25 up to 0.5 mg BPC-157 per day (the rest follows your ratio)
Community examples use 2 to 2.5 mg of total blend per day, or set the draw by GHK-Cu.
0.25 up to 0.5 mg BPC-157 per day (the rest follows the fixed ratio)
~0.1 mg CJC-1295 per dose, with the ipamorelin fixed at whatever ratio the vial was mixed at
Community examples use 2 to 4 mg of total blend per day, or set the draw by GHK-Cu.
1 up to 5 mg MOTS-c per day (the rest follows the fixed 10:1:1 ratio)
Research only
Research only
0.2 up to 0.5 mg sermorelin per dose (the GHRP-2 follows your ratio)
0.2 up to 0.5 mg sermorelin per dose (the GHRP-6 follows your ratio)
0.2 up to 0.5 mg sermorelin per dose (the ipamorelin follows your ratio)
1.28 up to 2 mg tesamorelin per day (the ipamorelin follows your ratio)
412 compounds, one number each
Someone actually measured this in a person.
Repeated widely. Traced to no study.
A course printed on the box, not a dose.
No human dose exists to cite.
A community dose is not necessarily wrong. It means that when we went looking for the study behind the number, there wasn’t one. Where the only figures online looked invented or were carried over from a different compound, we left them out and said why on that compound’s page. Skincare peptides and course products are counted separately, because a concentration in a finished serum and a course printed on a box are both different things from a dose. Read the guide explaining the source types. For GLP-1 medicines, why label doses and community doses differ matters too.
A label dose is for the approved product
FDA-label figures describe the approved drug at the strength and route it was approved for. A research vial sold under the same name was never tested against that label.
Numbers that repeat are usually copied
Many vendor pages print identical round numbers for unrelated compounds. That pattern usually means a figure was copied rather than measured. Seeing a number everywhere is not evidence for it.
A blend has one dose
A blend's dose is written against one component, and the others follow at whatever ratio is in the vial. See what each blend delivers
Does this chart tell me what dose to take?
No. It shows the dose people most often cite and where that number came from. For most compounds on this page nobody has tested a dose, and we say so rather than repeat a number.
Why do some compounds show no dose at all?
Because we could not trace one to a person. Some were only ever studied in cells or animals. For others, the figures online were invented or borrowed from a different compound, so we left them out and explain why on the compound's page.
Why do skincare peptides show a percentage instead of a dose?
They are applied in a finished product at a concentration the manufacturer sets. There is no injected dose to report, so the chart shows the concentration products use.
How do I turn a dose into a syringe reading?
Use the calculator. Enter your vial size, the water you added and your dose, and it gives the draw in units on a U-100 insulin syringe.
This page describes what people cite. It does not tell you what to do.